Immunome Historical Financial Ratios
| IMNM Stock | USD 8.18 0.48 5.54% |
Immunome is lately reporting on over 93 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 3.61 or Days Sales Outstanding of 6.02 will help investors to properly organize and evaluate Immunome financial condition quickly.
Immunome |
About Immunome Financial Ratios Analysis
ImmunomeFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Immunome investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Immunome financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Immunome history.
Immunome Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Immunome stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Immunome sales, a figure that is much harder to manipulate than other Immunome multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Stock Based Compensation To Revenue
A metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards.Capex To Depreciation
The ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets.Most ratios from Immunome's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Immunome current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunome. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.At this time, Immunome's Net Debt To EBITDA is very stable compared to the past year. As of the 23rd of March 2025, Current Ratio is likely to grow to 4.22, while Operating Cash Flow Per Share is likely to drop (1.98).
| 2022 | 2023 | 2024 | 2025 (projected) | Current Ratio | 3.09 | 6.63 | 4.08 | 4.22 | Net Debt To EBITDA | 0.55 | 3.43 | 0.92 | 1.09 |
Immunome fundamentals Correlations
Click cells to compare fundamentals
Immunome Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Immunome fundamentals Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Ptb Ratio | 2.37 | 3.1 | 1.61 | 1.77 | 3.44 | 3.61 | |
| Book Value Per Share | 4.09 | 4.18 | 1.37 | 6.04 | 3.09 | 3.24 | |
| Operating Cash Flow Per Share | (1.2) | (1.58) | (2.37) | (0.38) | (1.89) | (1.98) | |
| Capex To Depreciation | 0.78 | 0.1 | 0.39 | 1.14 | 3.41 | 3.58 | |
| Pb Ratio | 2.37 | 3.1 | 1.61 | 1.77 | 3.44 | 3.61 | |
| Free Cash Flow Per Share | (1.26) | (1.59) | (2.39) | (0.42) | (2.01) | (2.11) | |
| Roic | (0.28) | (0.51) | (2.21) | (0.86) | (1.64) | (1.73) | |
| Net Income Per Share | (1.69) | (2.12) | (3.09) | (5.38) | (5.0) | (5.25) | |
| Payables Turnover | 0.64 | 0.25 | 0.26 | 6.92 | 6.23 | 6.54 | |
| Cash Per Share | 3.93 | 4.27 | 1.68 | 6.96 | 3.71 | 2.57 | |
| Pocfratio | (8.07) | (8.2) | (0.93) | (28.06) | (5.62) | (5.9) | |
| Interest Coverage | (97.62) | (322.66) | (2.5K) | (7.4K) | (8.5K) | (8.1K) | |
| Capex To Operating Cash Flow | (0.0483) | (0.004334) | (0.008644) | (0.11) | (0.0647) | (0.068) | |
| Pfcf Ratio | (7.69) | (8.17) | (0.93) | (25.28) | (5.28) | (5.54) | |
| Days Payables Outstanding | 573.85 | 1.5K | 1.4K | 52.72 | 47.44 | 45.07 | |
| Income Quality | 0.68 | 0.74 | 0.78 | 0.0709 | 0.38 | 0.7 | |
| Roe | (0.41) | (0.51) | (2.25) | (0.89) | (1.62) | (1.54) | |
| Ev To Operating Cash Flow | (4.84) | (5.52) | (0.24) | (15.23) | (4.37) | (4.59) | |
| Pe Ratio | (5.72) | (6.11) | (0.71) | (1.99) | (2.13) | (2.23) | |
| Return On Tangible Assets | (0.38) | (0.42) | (1.56) | (0.72) | (1.22) | (1.28) | |
| Ev To Free Cash Flow | (4.62) | (5.5) | (0.23) | (13.73) | (4.1) | (4.31) | |
| Earnings Yield | (0.17) | (0.16) | (1.4) | (0.5) | (0.47) | (0.49) | |
| Net Debt To E B I T D A | 2.3 | 2.04 | 0.55 | 3.43 | 0.92 | 1.09 | |
| Current Ratio | 14.12 | 5.82 | 3.09 | 6.63 | 4.08 | 4.22 | |
| Tangible Book Value Per Share | 4.09 | 4.18 | 1.37 | 6.04 | 3.09 | 3.24 | |
| Shareholders Equity Per Share | 4.09 | 4.18 | 1.37 | 6.04 | 3.09 | 3.24 | |
| Debt To Equity | 0.0148 | 0.006579 | 0.0176 | 0.0138 | 0.0267 | 0.028 | |
| Capex Per Share | 0.058 | 0.006847 | 0.0205 | 0.0419 | 0.12 | 0.0783 | |
| Graham Net Net | 3.64 | 3.52 | 1.08 | 5.53 | 2.7 | 2.83 | |
| Interest Debt Per Share | 0.0644 | 0.0283 | 0.0246 | 0.0832 | 0.0824 | 0.0783 | |
| Debt To Assets | 0.0138 | 0.005473 | 0.0122 | 0.0111 | 0.0201 | 0.0191 | |
| Enterprise Value Over E B I T D A | (3.45) | (4.2) | (0.19) | (4.08) | (3.2) | (3.36) | |
| Price Earnings Ratio | (5.72) | (6.11) | (0.71) | (1.99) | (2.13) | (2.23) | |
| Price Book Value Ratio | 2.37 | 3.1 | 1.61 | 1.77 | 3.44 | 3.61 | |
| Price Earnings To Growth Ratio | 0.7 | (0.24) | (0.0156) | (0.0268) | 0.3 | 0.15 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunome. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunome. If investors know Immunome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunome listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.00) | Revenue Per Share | Quarterly Revenue Growth (0.28) | Return On Assets | Return On Equity |
The market value of Immunome is measured differently than its book value, which is the value of Immunome that is recorded on the company's balance sheet. Investors also form their own opinion of Immunome's value that differs from its market value or its book value, called intrinsic value, which is Immunome's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunome's market value can be influenced by many factors that don't directly affect Immunome's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunome's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunome is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunome's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.